Category: Pharma Industry

Two Drug Makers Post Manufacturer Notices for 340B Overcharges

August 17, 2023 William Newton, Associate Editor/Senior Writer Views

Meitheal Pharmaceuticals and Purdue Pharma are each sending 340B covered entities refunds for overcharges totaling $100 or more.

Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Lobbying Activity Experiences Historic Surge

August 15, 2023 Rich Daly, Editor in Chief Views

Key House Republicans on Tuesday introduced long-awaited—and contentious—legislation to overhaul the 340B program.

The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law

August 15, 2023 William Newton, Associate Editor/Senior Writer Views

AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.

Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases

August 15, 2023 Tom Mirga, Editor at Large Views

Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.

GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Five Major Drug Makers Oppose Health Center’s Legal Challenge to 340B Patient Definition

August 8, 2023 Tom Mirga, Editor at Large Views

AbbVie, BMS, Lilly, and Merck jointly asked a federal district court to dismiss a health center’s challenge to the 340B patient definition. Drug maker Janssen asked the same separately.

Drug makers AbbVie, Bristol Myers Squibb, Janssen, Lilly, and Merck asked a federal district court in South Carolina on Friday [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

August 8, 2023 Rich Daly, Editor in Chief Views

A Moran Company study, funded by PhRMA, found 340B hospitals charge an average of 500% above acquisition costs for 20 high-cost drugs.

Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Merck Loosens 340B Contract Pharmacy Restrictions in Two States as Louisiana Law Takes Effect

August 3, 2023 William Newton, Associate Editor/Senior Writer Views

Merck is the first drug manufacturer to announce it is issuing refunds to 340B providers in 2024.

Drug manufacturer Merck recently loosened its 340B program contract pharmacy restrictions in Louisiana and Arkansas just before Louisiana’s law protecting [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Louisiana’s New 340B Contract Pharmacy Law Goes Into Effect Today; PhRMA Sues and Teva Suspends its Restrictions in the State

August 1, 2023 William Newton, Associate Editor/Senior Writer Views

Brand drug trade group PhRMA is suing Louisiana over its law protecting 340B contract pharmacy arrangements.

Today is the first day of Louisiana’s new law protecting 340B program contract pharmacy arrangements and there have already been [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Amgen, Vertex, and AstraZeneca Post 340B Refund and Replenishment Public Notices

July 27, 2023 Tom Mirga, Editor at Large Views

Aranesp is among the drugs listed on HRSA's latest manufacturer's notice posted on behalf of Amgen.

The U.S. Health Resources and Services Administration (HRSA) this week published notices from drug makers Amgen and Vertex about refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative

July 25, 2023 Tom Mirga, Editor at Large Views

340B Working Table 340B lobbying disclosure form

Under the name 340B Working Table, Genentech, Sanford Health, and Carolina Health Centers are jointly lobbying for a bipartisan U.S. Senate 340B reform initiative.

Biopharmaceutical manufacturer Genentech, South Dakota-based health system Sanford Health, and South Carolina federally qualified health center Carolina Health Centers are jointly lobbying members of Congress to back six U.S. senators’ bipartisan approach to federal 340B program reform, the three organizations

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Exclusive

Site Footer Live